AURA · Aura Biosciences Inc

Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. It focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer. The company was incorporated in 2009 and is headquartered in Boston, Massachusetts.

80 Guest Street, Boston, MA, 02135, United States
Biotechnology
Healthcare

Market Cap

715M

52 Wk Range

$4.73 - $9.54

Previous Close

$6.98

Open

$6.50

Volume

791,134

Day Range

$6.50 - $6.98

Enterprise Value

445.4M

Cash

297.2M

Avg Qtr Burn

-26.44M

Insider Ownership

2.41%

Institutional Own.

N/A

Qtr Updated

Sep 30th 2026